Lucemyra is an oral selective alpha 2-adrenergic receptor agonist
The efficacy of Aimovig was evaluated as a preventive treatment of episodic or chronic migraine in 3 randomized, double-blind, placebo-controlled studies: 2 studies in patients with episodic migraine (4-14 migraine days per month) and 1 study in patients with chronic migraine (≥15 headache days per month with ≥8 migraine days per month).
Gilenya is the first multiple sclerosis drug approved for children
The FDA advisory committee voted 12-2 in favor of recommending the approval of Nuplazid.
Switching back to branded drugs is more likely in generic drug than authorized generic drugs.
The FDA has approved Rubraca, a poly (ADP-ribose) polymerase inhibitor, to treat patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
The proposed pediatric indications are based on a 2018 Draft Guidance that supports extrapolating efficacy data of approved drugs to treat POS in adults to pediatric patients aged ≥4 years.
Does weak evidence drive the NCCN recommendations of FDA-approved drugs?
A new antiretroviral HIV treatment, Trogarzo (ibalizumab-uiyk), has been approved by the FDA for patients with HIV who have not have success with past HIV medications.
The new FDA approved short-acting insulin drug can be used to treat T1 and T2 diabetes.
The FDA has approved two new treatments, Tresiba and Ryzodeg, for both type 1 and type 2 diabetes.
The drug is approved for patients who are unable to control their LDL cholesterol with current treatment options.
The FDA approval of a pediatric indication for Oxycontin creates a safer situation for terminally ill children.
The FDA has approved a pediatric indication for OxyContin in patients as young as 11 years.
An intragastric balloon receives approval as a non-surgical weight loss procedure for patients with mild-to-moderate obesity.
Two new therapies to treat irritable bowel syndrome, eluxadoline and rifaximin, have been approved by the FDA.
Spray-dried fibrin sealant promotes clotting when other methods are "ineffective or impractical."
The FDA has granted expanded the use of Eylea injection to treat diabetic retinopathy in patients with diabetic macular edema (DME).
New drug targets cell walls of the fungi and is available in oral and intravenous formulations.
The FDA has approved Cohera Medical's TissuGlu Surgical Adhesive, the first tissue adhesive for internal use.
The FDA has approved empagliflozin/linagliptin tablets as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when both empagliflozin and linagliptin are appropriate treatments.
The FDA has approved esomeprazole magnesium delayed-release capsules, the first generic version of AstraZeneca's Nexium.
Perindopril arginine and amlodipine besylate may be used as initial therapy if a patient is likely to need multiple drugs to achieve their blood pressure goals.
Secukinumab has been approved by the FDA for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Savaysa (edoxaban) is indicated to treat deep vein thrombosis and pulmonary embolism and prevent stroke.
The FDA has approved Saxenda (liraglutide [rDNA origin]) injection for chronic weight management.
Patients given paramivir had flu symptoms ease 21 hours sooner compared with patients left untreated.
The FDA has approved Trumenba, the first vaccine approved in the U.S. to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B
Results showed that patients who took Contrave had an average weight loss of 4.1% more compared with patients who were assigned placebo.
The FDA has approved three drugs to treat ABSSI in 2014.